Achaogen to Present at the Wedbush PacGrow Healthcare Conference
08 août 2017 16h01 HE
|
Achaogen Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug...
Achaogen Reports Second Quarter 2017 Financial Results and Provides Corporate Update
03 août 2017 16h01 HE
|
Achaogen Inc.
-- Plazomicin granted Breakthrough Therapy designation -- -- C-Scape Phase 1 study underway to evaluate orally-administered antibacterial candidate for infections due to ESBL-producing...
Achaogen to Host Conference Call and Webcast of Second Quarter 2017 Financial Results on August 3, 2017
27 juil. 2017 08h01 HE
|
Achaogen Inc.
SOUTH SAN FRANCISCO, Calif., July 27, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing...
Achaogen Wins CARB-X Funding Award to Advance Development of LpxC Inhibitor Antibiotic to Fight Drug Resistant Infections
25 juil. 2017 08h01 HE
|
Achaogen Inc.
-- CARB-X funding highlights Achaogen’s innovative LpxC program and urgent need for gram-negative antibiotics -- -- Awarded $3.2 million over 12 months, and potentially up to a total award of $11.4...
Achaogen Announces New Employment Inducement Grants
24 juil. 2017 08h01 HE
|
Achaogen Inc.
SOUTH SAN FRANCISCO, Calif., July 24, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug...
Achaogen Appoints Dr. Karen Bernstein to its Board of Directors
13 juil. 2017 08h01 HE
|
Achaogen Inc.
SOUTH SAN FRANCISCO, Calif., July 13, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug...
Achaogen Announces New Employment Inducement Grants
22 juin 2017 08h01 HE
|
Achaogen Inc.
SOUTH SAN FRANCISCO, Calif., June 22, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug...
Achaogen Highlights Data Demonstrating Potential of Plazomicin Against MDR Gram-Negative Bacteria at ASM Microbe 2017 Annual Meeting
05 juin 2017 08h00 HE
|
Achaogen Inc.
-- Oral presentations highlighted data from plazomicin Phase 3 EPIC and CARE clinical trials -- -- Newly-released in vitro data demonstrated potent activity of plazomicin against contemporary...
Achaogen Initiates C-Scape Clinical Development Program with Phase 1 Study of Orally-Administered Antibacterial Candidate
01 juin 2017 08h00 HE
|
Achaogen Inc.
-- Clinical trial to evaluate orally-administered beta-lactam/beta-lactamase inhibitor combination being developed for infections due to extended spectrum beta-lactamase (ESBL)-producing...
Achaogen Announces Closing of Public Offering
31 mai 2017 16h01 HE
|
Achaogen Inc.
SOUTH SAN FRANCISCO, Calif., May 31, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing...